UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 30, 2007

NEOPROBE CORPORATION
(Exact name of registrant as specified in its charter)

Delaware	0-26520	31-1080091
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

425 Metro Place North, Suite 300, Columbus, Ohio	43017
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code (614) 793-7500

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On October 30, 2007, Neoprobe Corporation (the "Company") issued a press release regarding its consolidated financial results for the third quarter ended September 30, 2007. A copy of the Company's October 30, 2007, press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in Item 2.02 of this Current Report on Form 8-K, including exhibit 99.1 hereto, shall not be treated as "filed" for purposes of the Securities Exchange Act of 1934, as amended.

Item 8.01. Other Events.

On October 30, 2007, the Company also issued a press release announcing that the Company held an end of Phase 2 meeting with the U.S. Food and Drug Administration (the "FDA") to review the conduct of a successfully completed multicenter Phase 2 study of Lymphoseek. In addition, the Company and the FDA reviewed proposed protocols for Phase 3 clinical studies of Lymphoseek. At the conclusion of the discussion, the Company and the FDA were in concurrence regarding the design of the Phase 3 studies. A copy of the complete text of the Company's October 30, 2007, press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Statements contained or incorporated by reference in this Current Report on Form 8-K which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, and markets for the Company's products, are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, and other risks detailed in the Company's most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	*Exhibit Description*
99.1	Neoprobe Corporation press release dated October 30, 2007, entitled "Neoprobe Announces Third Quarter Results."
99.2	Neoprobe Corporation press release dated October 30, 2007, entitled "Neoprobe Completes FDA Meeting Regarding Lymphoseek."

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Neoprobe Corporation

Date: October 30, 2007

By: /s/ Brent L. Larson
Brent L. Larson, Vice President, Finance and
Chief Financial Officer

IMMEDIATE RELEASE
CONTACTS:
Brent Larson,
Vice President / CFO
614 822.2330

October 30, 2007

Tim Ryan,
The Trout Group
646.378.2924

NEOPROBE ANNOUNCES THIRD QUARTER RESULTS
Quarterly Sales Increase 107% and YTD Sales Increase 26%
Business Update Provided and Conference Call Scheduled

DUBLIN, OHIO - October 30, 2007 -- Neoprobe Corporation (OTCBB:NEOP - News), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced consolidated results for the third quarter of 2007 and for the nine-month period ended September 30, 2007. For the third quarter of 2007, Neoprobe reported a net loss of $942,000 or $0.01 per share compared to a net loss of $1.7 million or $0.03 per share for the third quarter in 2006. For the nine months ended September 30, 2007, Neoprobe reported a net loss of $3.2 million or $0.05 per share compared to a net loss of $3.4 million or $0.06 per share for the same period in 2006. The net loss for the third quarter of 2007 included $755,000 in non-cash charges compared to total non-cash charges of $362,000 for the third quarter of 2006. The net loss for the nine-month period ended September 30, 2007 included $1.5 million in non-cash charges compared to total non-cash charges of $1.1 million for the same period in 2006. Non-cash charges for both periods consisted primarily of the amortization of warrant and debt-issuance costs in addition to depreciation and amortization of fixed and intangible assets.

Brent Larson, Neoprobe's Vice President, Finance and CFO, said, "Device revenue for the third quarter of 2007 increased 107% or $1.0 million over the same quarter last year and is up 26% overall for the year-to-date period ending September 30, 2007. Revenue related to our new Bluetooth® wireless probes has been strong, more than offsetting the decline in sales of our blood flow devices. Year-to-date revenue from our gamma detection systems overall was $5.0 million compared to $3.8 million for the comparable period in 2006. In the third quarter of 2007, Neoprobe's gamma device product revenue increased 110% and year-to-date 2007 gamma product revenue has increased 31% over the comparable periods in 2006. Year-to-date sales of blood flow devices totaled $285,000 for the first nine months of 2007 compared to $391,000 for the same period in 2006. Year-to-date gross margins from combined device sales decreased slightly to 56% from 58% reflecting production start-up expenses and lower-margin demonstration unit placements for Bluetooth probes in 2007 as compared to 2006. We expect margins to recover to historical levels over the remainder of the year as awareness of our new Bluetooth product offering continues to grow."

David Bupp, Neoprobe's President and CEO, said, "Our research and development expenses decreased $431,000 or 16% for the first nine months of 2007 compared to last year. The costs of clinical trial activities related to the recently completed Phase 2 trial for Lymphoseek, coupled with decreased device development activities through September 30, 2007, resulted in lower overall R&D expenses than the costs of drug manufacturing validation and production activities that occurred during the first nine months on 2006. General and administrative costs also declined 6% on a year-to-date basis compared to the prior year."

Following are some of the milestones achieved by Neoprobe during the third quarter 2007:

- Achieved and reported positive final results from the Phase 2 Lymphoseek trial in breast cancer and melanoma. Based upon final pathology confirmed results Lymphoseek identified lymphatic tissue in over 95% of the surgically treated patients.
- Closed on a $1 million investment in the Company led by our President and CEO, David Bupp.

- more -

- Executed a definitive term sheet for the marketing and distribution of Lymphoseek in the United States with the nuclear pharmacy division of Cardinal Health and completed drafts of definitive distribution contracts.
- Commenced development activities for the Phase 3 clinical studies of Lymphoseek including a submission of end of Phase 2 and pre-Phase 3 meeting materials to FDA.

"Successful completion of the Phase 2 trial for Lymphoseek in breast cancer and melanoma coupled with the execution of a definitive term sheet for Lymphoseek distribution with the overwhelming market leader in radiopharmaceutical distribution in the United States are the most solid demonstrations yet of the potential for Lymphoseek and for Neoprobe in general," Bupp continued. "We are moving forward with preparations for pivotal Phase 3 trials for Lymphoseek as our core device business continues to consistently perform. We grow more excited each day with the future of the Company."

Neoprobe's President and CEO, David Bupp, and Vice President, Finance and CFO, Brent Larson, will provide a business update and discuss the company's results for the third quarter of 2007 during the conference call scheduled for 11:00AM ET, Wednesday, October 31, 2007. The conference call can be accessed as follows:

Conference Call Information			
TO PARTICIPATE LIVE:		**TO LISTEN TO A REPLAY:**	
Date:	October 31, 2007	Available until:	November 7, 2007
Time:	11:00AM EDT	Toll-free (U.S.) Dial in # :	877-660-6853
		International Dial in # :	201-612-7415
Toll-free (U.S.) Dial in # :	877-407-8033	Replay Passcodes (both required for playback):	
International Dial in # :	201-689-8033	Account # :	286
		Conference ID # :	259905

About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000® line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix® line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan® CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions.www.neoprobe.com

Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

- more -

NEOPROBE CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2007 (unaudited)	December 31, 2006
Assets:		
Cash	$ 1,219,101	$ 2,502,655
Other current assets	2,645,887	2,831,088
Intangible assets, net	1,657,507	1,828,517
Other non-current assets	529,797	871,272
Total assets	$ 6,052,292	$ 8,033,532
Liabilities and stockholders' deficit:		
Current liabilities, including current portion of notes payable	$ 5,927,394	$ 3,409,252
Notes payable, long term (net of discounts)	2,106,304	4,862,125
Other liabilities	105,950	60,182
Stockholders' deficit	(2,087,356)	(298,027)
Total liabilities and stockholders' deficit	$ 6,052,292	$ 8,033,532

NEOPROBE CORPORATION
ADD - 4

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended		Nine Months Ended	
	September 30, 2007 (unaudited)	September 30, 2006 (unaudited)	September 30, 2007 (unaudited)	September 30, 2006 (unaudited)
Net sales	$ 1,985,049	$ 957,952	$ 5,245,799	$ 4,179,861
Cost of goods sold	836,436	403,190	2,325,772	1,741,172
Gross profit	1,148,613	554,762	2,920,027	2,438,689
Operating expenses:				
Research and development	548,455	1,241,899	2,287,600	2,718,655
Selling, general and administrative	690,206	651,419	2,123,075	2,257,714
Total operating expenses	1,238,661	1,893,318	4,410,675	4,976,369
Loss from operations	(90,048)	(1,338,556)	(1,490,648)	(2,537,680)
Interest expense	(862,762)	(371,013)	(1,749,609)	(1,090,973)
Other income, net	11,032	53,202	52,940	183,215
Net loss	$ (941,778)	$ (1,656,367)	$ (3,187,317)	$ (3,445,438)
Loss per common share:				
Basic	$ (0.01)	$ (0.03)	$ (0.05)	$ (0.06)
Diluted	$ (0.01)	$ (0.03)	$ (0.05)	$ (0.06)
Weighted average shares outstanding:				
Basic	63,756,043	58,560,046	61,687,077	58,543,859
Diluted	63,756,043	58,560,046	61,687,077	58,543,859

IMMEDIATE RELEASE
CONTACTS:
Brent Larson,
Vice President / CFO
614 822 2330

October 30, 2007

Tim Ryan,
The Trout Group
646 378 2924

NEOPROBE COMPLETES FDA MEETING REGARDING LYMPHOSEEK®
Phase 2 Results and Phase 3 Protocols Reviewed

DUBLIN, OHIO - October 30, 2007 - Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that they held an end of Phase 2 meeting with U.S. Food and Drug Administration (FDA) to review the conduct of a successfully completed multicenter Phase 2 study of Lymphoseek®. In addition, Neoprobe and FDA reviewed proposed protocols for Phase 3 clinical studies of Lymphoseek. At the conclusion of the discussion, Neoprobe and FDA were in concurrence regarding the design of the Phase 3 studies.

David Bupp, President and CEO, said, "Meeting with FDA to review our completed clinical and development activities for Lymphoseek was an important corporate milestone. The Phase 3 trials as discussed with FDA will evaluate the concordance of the targeting of lymph nodes with Lymphoseek as compared to a blue dye commonly used in lymphatic mapping procedures. Neoprobe needs to respond to FDA's comments regarding the Phase 3 protocols. We expect a response to FDA comments will be filed shortly, along with the formal Phase 2 study report. In the interim, activities are underway to initiate the Phase 3 studies after appropriate final clearances from FDA and with the appropriate reviews by the investigational sites."

About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000® line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix® line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan® CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions.www.neoprobe.com

Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.